PPARA and metabolic dysfunction-associated steatotic liver disease: However, in the current study of the clinical relevance to nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, most research has focused on the efficacy of lanifibranor, a next-generation high-potential indole sulfonamide derivative, an anti-NASH drug, currently in clinical trial phase III [27], designed to target and ensure the well-balanced activation of all three subtypes of PPAR.